TY - JOUR AU - Heeley E. AU - Stapf C. AU - Robinson T. AU - Wang J. AU - Wang X. AU - Hirakawa Y. AU - Woodward Mark AU - Arima H. AU - Delcourt C. AU - Anderson Craig AU - Huang Y. AU - Lavados P. AU - Parsons M. AU - Chalmers J. AB -

OBJECTIVES: To investigate the effects of intensive blood pressure (BP) lowering according to baseline BP levels and optimal achieved BP levels in patients with acute intracerebral hemorrhage (ICH). METHODS: INTERACT2 was an open, blinded endpoint, randomized controlled trial in 2,839 patients with ICH within 6 hours of onset and elevated systolic BP (SBP) (150-220 mm Hg) who were allocated to receive intensive (target SBP <140 mm Hg within 1 hour, with lower limit of 130 mm Hg for treatment cessation) or guideline-recommended (target SBP <180 mm Hg) BP-lowering treatment. Outcome was physical function across all 7 levels of the modified Rankin Scale at 90 days. RESULTS: Analysis of the randomized comparisons showed that intensive BP lowering produced comparable benefits on physical function at 90 days in 5 subgroups defined by baseline SBP of <160, 160-169, 170-179, 180-189, and >/=190 mm Hg (p homogeneity = 0.790). Analyses of achieved BP showed linear increases in the risk of physical dysfunction for achieved SBP above 130 mm Hg for both hyperacute (1-24 hours) and acute (2-7 days) phases while modest increases were also observed for achieved SBP below 130 mm Hg. CONCLUSIONS: Intensive BP lowering appears beneficial across a wide range of baseline SBP levels, and target SBP level of 130-139 mm Hg is likely to provide maximum benefit in acute ICH. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that the effect of intensive BP lowering on physical function is not influenced by baseline BP.

AD - From The George Institute for Global Health (H.A., E.H., C.D., Y.H., X.W., M.W., J.C., C.S.A.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease (T.R.), University of Leicester, UK; Department of Neurology (C.S.), APHP, Hopital Lariboisiere and DHU NeuroVasc Paris, Sorbonne, Universite Paris Diderot, Sorbonne Paris Cite, Paris, France; Department of Neurology (M.P.), John Hunter Hospital, University of Newcastle, Australia; Servicio de Neurologia (P.M.L.), Departamento de Medicina, Clinica Alemana, Universidad del Desarrollo, Santiago; Departamento de Ciencias Neurologicas (P.M.L.), Universidad de Chile, Santiago; Department of Neurology (Y.H.), Peking University First Hospital, Beijing; and The Shanghai Institute of Hypertension (J.W.), Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China.
From The George Institute for Global Health (H.A., E.H., C.D., Y.H., X.W., M.W., J.C., C.S.A.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; Department of Cardiovascular Sciences and NIHR Biomedical Research Unit in Cardiovascular Disease (T.R.), University of Leicester, UK; Department of Neurology (C.S.), APHP, Hopital Lariboisiere and DHU NeuroVasc Paris, Sorbonne, Universite Paris Diderot, Sorbonne Paris Cite, Paris, France; Department of Neurology (M.P.), John Hunter Hospital, University of Newcastle, Australia; Servicio de Neurologia (P.M.L.), Departamento de Medicina, Clinica Alemana, Universidad del Desarrollo, Santiago; Departamento de Ciencias Neurologicas (P.M.L.), Universidad de Chile, Santiago; Department of Neurology (Y.H.), Peking University First Hospital, Beijing; and The Shanghai Institute of Hypertension (J.W.), Rui Jin Hospital, Shanghai Jiaotong University, Shanghai, China. canderson@georgeinstitute.org.au. AN - 25552575 BT - Neurology DP - NLM ET - 2015/01/02 LA - Eng LB - PDO
NMH M1 - 5 N1 - Arima, Hisatomi
Heeley, Emma
Delcourt, Candice
Hirakawa, Yoichiro
Wang, Xia
Woodward, Mark
Robinson, Thompson
Stapf, Christian
Parsons, Mark
Lavados, Pablo M
Huang, Yining
Wang, Jiguang
Chalmers, John
Anderson, Craig S
For the INTERACT2 Investigators
Neurology. 2014 Dec 31. pii: 10.1212/WNL.0000000000001205. N2 -

OBJECTIVES: To investigate the effects of intensive blood pressure (BP) lowering according to baseline BP levels and optimal achieved BP levels in patients with acute intracerebral hemorrhage (ICH). METHODS: INTERACT2 was an open, blinded endpoint, randomized controlled trial in 2,839 patients with ICH within 6 hours of onset and elevated systolic BP (SBP) (150-220 mm Hg) who were allocated to receive intensive (target SBP <140 mm Hg within 1 hour, with lower limit of 130 mm Hg for treatment cessation) or guideline-recommended (target SBP <180 mm Hg) BP-lowering treatment. Outcome was physical function across all 7 levels of the modified Rankin Scale at 90 days. RESULTS: Analysis of the randomized comparisons showed that intensive BP lowering produced comparable benefits on physical function at 90 days in 5 subgroups defined by baseline SBP of <160, 160-169, 170-179, 180-189, and >/=190 mm Hg (p homogeneity = 0.790). Analyses of achieved BP showed linear increases in the risk of physical dysfunction for achieved SBP above 130 mm Hg for both hyperacute (1-24 hours) and acute (2-7 days) phases while modest increases were also observed for achieved SBP below 130 mm Hg. CONCLUSIONS: Intensive BP lowering appears beneficial across a wide range of baseline SBP levels, and target SBP level of 130-139 mm Hg is likely to provide maximum benefit in acute ICH. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that the effect of intensive BP lowering on physical function is not influenced by baseline BP.

PY - 2014 SN - 1526-632X (Electronic)
0028-3878 (Linking) SP - 464 EP - 71 T2 - Neurology TI - Optimal achieved blood pressure in acute intracerebral hemorrhage: INTERACT2 VL - 84 ER -